{"protocolSection":{"identificationModule":{"nctId":"NCT01226511","orgStudyIdInfo":{"id":"12929"},"secondaryIdInfos":[{"id":"F1J-MC-HMGI","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study in Pediatric Participants With Generalized Anxiety Disorder","officialTitle":"A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder"},"statusModule":{"statusVerifiedDate":"2014-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-06"},"primaryCompletionDateStruct":{"date":"2013-02","type":"ACTUAL"},"completionDateStruct":{"date":"2013-06","type":"ACTUAL"},"studyFirstSubmitDate":"2010-10-12","studyFirstSubmitQcDate":"2010-10-21","studyFirstPostDateStruct":{"date":"2010-10-22","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-01-17","resultsFirstSubmitQcDate":"2014-01-17","resultsFirstPostDateStruct":{"date":"2014-03-05","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-01-17","lastUpdatePostDateStruct":{"date":"2014-03-05","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to find out if duloxetine \\[30-120 milligrams (mg)\\] given once a day by mouth for 10 weeks to children and adolescents, is better than placebo when treating Generalized Anxiety Disorder (GAD)."},"conditionsModule":{"conditions":["Anxiety Neuroses","Anxiety States, Neurotic","Neuroses, Anxiety"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":281,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Duloxetine","type":"EXPERIMENTAL","description":"30-120 mg flexible dosing once daily for 10 weeks. At the end of the 10 week blinded treatment period, participants may participate in an 18 week extension","interventionNames":["Drug: Duloxetine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Administered once daily for 10 weeks. At the end of the 10 week blinded treatment period, placebo participants receive duloxetine in the 18 week extension","interventionNames":["Drug: Duloxetine","Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Duloxetine","description":"Administered orally","armGroupLabels":["Duloxetine","Placebo"],"otherNames":["Cymbalta","LY248686"]},{"type":"DRUG","name":"Placebo","description":"Administered orally","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline to 10-Week Endpoint in the Pediatric Anxiety Rating Scale (PARS) Severity Score Evaluated for Symptoms Identified on the Generalized Anxiety Subsection of the PARS Symptom Checklist","description":"PARS severity score for GAD was assessed for all symptoms identified in the generalized anxiety section of the PARS symptom checklist. PARS severity score for GAD was derived by summing 5 of 7 severity/impairment/interference items (2, 3, 5, 6, 7); each item ranged from 0 (none) to 5 (extreme severity/impairment/interference). PARS severity scores for GAD ranged from 0 (none) to 25 (extreme severity), with a score of 15 indicating moderate illness severity. Least squares (LS) mean was calculated using a mixed-effects model repeated measures (MMRM) approach adjusted for baseline, pooled investigator, age category, visit, treatment, treatment\\*visit, age category\\*visit, and baseline\\*visit.","timeFrame":"Baseline, 10 weeks"}],"secondaryOutcomes":[{"measure":"Response Rate at Endpoint for Generalized Anxiety Disorder (GAD) Using Pediatric Anxiety Rating Scale (PARS) Severity Score for GAD","description":"Response rate was defined as the percentage of participants having a 50% improvement from baseline to endpoint on the PARS severity score for GAD. PARS severity score for GAD was assessed for all symptoms identified in the generalized anxiety section of the PARS symptom checklist. PARS severity score for GAD was derived by summing 5 of 7 severity/impairment/interference items (2, 3, 5, 6, 7); each item ranged from 0 (none) to 5 (extreme severity/impairment/interference). PARS severity scores for GAD ranged from 0 (none) to 25 (extreme severity), with a score of 15 indicating moderate illness severity.","timeFrame":"Baseline, 10 weeks"},{"measure":"Change From Baseline to 10-Week Endpoint on the Pediatric Anxiety Rating Scale (PARS) Severity Total Score Evaluated for All Symptoms Identified on the PARS Symptom Checklist Symptoms","description":"PARS severity total score was assessed for all symptoms identified on the PARS symptom checklist. PARS severity total score was derived by summing 5 of 7 severity/impairment/interference items (2, 3, 5, 6, 7); each item ranged from 0 (none) to 5 (extreme severity/impairment/interference). PARS severity total scores ranged from 0 (none) to 25 (extreme severity), with a score of 15 indicating moderate illness severity. Least squares (LS) mean was calculated using a mixed-effects model repeated measures (MMRM) approach adjusted for treatment, pooled investigator, visit, baseline, age category, treatment\\*visit, baseline\\*visit, and age category\\*visit.","timeFrame":"Baseline, 10 weeks"},{"measure":"Change From Baseline to 10-Week Endpoint on the Clinical Global Impression of Severity (CGI-S) Scale","description":"The CGI-S scale evaluated the severity of illness at the time of assessment. Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill). Higher scores indicated a greater severity of illness. Least squares (LS) mean was calculated using a mixed-effects model repeated measures (MMRM) approach adjusted for treatment, pooled investigator, visit, baseline, age category, treatment\\*visit, baseline\\*visit, and age category\\*visit.","timeFrame":"Baseline, 10 weeks"},{"measure":"Remission Rate at Endpoint for Generalized Anxiety Disorder (GAD) Using Clinical Global Impressions of Severity (CGI-S) Scale","description":"Remission rate was defined as the percentage of participants having a CGI-S score ≤2 at endpoint. The CGI-S scale evaluated the severity of illness at the time of assessment. Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill). Higher scores indicated a greater severity of illness.","timeFrame":"10 weeks"},{"measure":"Change From Baseline to 10-Week Endpoint in the Children's Global Assessment Scale (CGAS)","description":"The CGAS was a clinician-rated assessment of general functioning. CGAS raw scores ranged from 1 (greatest impairment) to 100 (superior functioning). Lower scores indicated a lower level of functioning and greater impairment. Least squares (LS) mean from an analysis of covariance (ANCOVA) was adjusted for treatment, pooled investigator, baseline, and age category.","timeFrame":"Baseline, 10 weeks"},{"measure":"Percentage of Participants During the 10-Week Period With Treatment-Emergent (New or Worsening) Suicidal Ideation as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)","description":"The C-SSRS captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal ideation: a \"yes\" answer to any 1 of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Results reported as percentage of participants with treatment-emergent (new or worsening) suicidal ideation from baseline=(number of participants with changes compared to baseline/total number of participants at risk)\\*100.","timeFrame":"Baseline up to 10 weeks"},{"measure":"Percentage of Participants During the 10-Week Period With Treatment-Emergent (New or Worsening) Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)","description":"The C-SSRS captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior: a \"yes\" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Reported as percentage of participants with treatment-emergent (new or worsening) suicidal behavior from baseline=(number of participants with changes compared to baseline/total number of participants at risk)\\*100.","timeFrame":"Baseline up to 10 weeks"},{"measure":"Change From 10-Week to 28-Week Endpoint in the Pediatric Anxiety Rating Scale (PARS) Severity Score Evaluated for Symptoms Identified on the Generalized Anxiety Subsection of the PARS Symptom Checklist","description":"PARS severity score for GAD was assessed for all symptoms identified in the generalized anxiety section of the PARS symptom checklist. PARS severity score for GAD was derived by summing 5 of 7 severity/impairment/interference items (2, 3, 5, 6, 7); each item ranged from 0 (none) to 5 (extreme severity/impairment/interference). PARS severity scores for GAD ranged from 0 (none) to 25 (extreme severity), with a score of 15 indicating moderate illness severity. Least squares (LS) mean was calculated using a mixed-effects model repeated measures (MMRM) approach adjusted for pooled investigator, visit, baseline, age category, baseline\\*visit, and age category\\*visit within reporting groups.","timeFrame":"10 weeks, 28 weeks"},{"measure":"Change From 10-Week to 28-Week Endpoint on the Pediatric Anxiety Rating Scale (PARS) Severity Total Score Evaluated for All Symptoms Identified on the PARS Symptom Checklist Symptoms","description":"PARS severity total score was assessed for all symptoms identified on the PARS symptom checklist. PARS severity total score was derived by summing 5 of 7 severity/impairment/interference items (2, 3, 5, 6, 7); each item ranged from 0 (none) to 5 (extreme severity/impairment/interference). PARS severity total scores ranged from 0 (none) to 25 (extreme severity), with a score of 15 indicating moderate illness severity. Least squares (LS) mean was calculated using a mixed-effects model repeated measures (MMRM) approach adjusted for pooled investigator, visit, baseline, age category, baseline\\*visit, and age category\\*visit within reporting groups.","timeFrame":"10 weeks, 28 weeks"},{"measure":"Change From 10-Week to 28-Week Endpoint on the Clinical Global Impression of Severity (CGI-S) Scale","description":"The CGI-S scale evaluated the severity of mental illness at the time of assessment. Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill). Higher scores indicated a greater severity of illness. Least squares (LS) mean was calculated using a mixed-effects model repeated measures (MMRM) approach adjusted for pooled investigator, visit, baseline, age category, baseline\\*visit, and age category\\*visit within reporting groups.","timeFrame":"10 weeks, 28 weeks"},{"measure":"Change From 10-Week to 28-Week Endpoint in the Children's Global Assessment Scale (CGAS)","description":"The CGAS was a clinician-rated assessment of general functioning. CGAS raw scores ranged from 1 (greatest impairment) to 100 (superior functioning). Lower scores indicated a lower level of functioning and greater impairment. Least squares (LS) mean from an analysis of covariance (ANCOVA) was adjusted for pooled investigator, baseline, and age category within reporting groups.","timeFrame":"10 weeks, 28 weeks"},{"measure":"Percentage of Participants During the 18-Week Extension Period With Treatment-Emergent (New or Worsening) Suicidal Ideation as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)","description":"The C-SSRS captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal ideation: a \"yes\" answer to any 1 of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Results reported as percentage of participants with treatment-emergent (new or worsening) suicidal ideation from baseline=(number of participants with changes compared to baseline/total number of participants at risk)\\*100.","timeFrame":"10 weeks up to 28 weeks"},{"measure":"Percentage of Participants During the 18-Week Extension Period With Treatment-Emergent (New or Worsening) Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)","description":"The C-SSRS captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior: a \"yes\" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Reported as percentage of participants with treatment-emergent (new or worsening) suicidal behavior from baseline=(number of participants with changes compared to baseline/total number of participants at risk)\\*100.","timeFrame":"10 weeks up to 28 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with GAD on clinical exam as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and supported by the Mini International Neuropsychiatric Interview for children and adolescents (MINI-Kid)\n* Diagnosis of moderate or greater severity of GAD as determined by the following:\n\n  * Presence of 4 or more symptoms identified on the generalized anxiety subsection of the Pediatric Anxiety Rating Scale (PARS) symptom checklist at screening and randomization. Two of which are excessive worry and dread or fearful anticipation (nonspecific)\n  * PARS severity score of 15 or more at screening and randomization for symptoms identified on the generalized anxiety subsection of PARS symptom checklist at screening and randomization\n  * Clinical Global Impressions of Severity (CGI-S) rating of 4 or more at screening and randomization\n  * Presence of significant social, academic, and/or familial dysfunction as determined by the Children's Global Assessment Scale (CGAS) score of 60 or less at screening and randomization\n* Female participants must test negative for pregnancy during screening Furthermore, female participants must agree to abstain from sexual activity or to use a reliable method of birth control as determined by the investigator during the study\n* Participant's parent/legal representative and participant, if capable, are judged to be reliable by the investigator to keep all appointments for clinical visits, tests, and procedures required by the protocol\n* Participant's parent/legal representative and participant, if capable, must have a degree of understanding such that they can communicate intelligently with the investigator and study coordinator\n* Participants must be capable of swallowing study drug whole (without opening the capsule, crushing, dissolving, dividing, et cetera)\n* Participants must have venous access sufficient to allow blood sampling and are compliant with blood draws as per the protocol\n\nExclusion Criteria:\n\n* Current diagnosis of major depressive disorder (MDD)\n* Participants for whom the primary focus of treatment is separation anxiety or social phobia (participants with secondary separation anxiety or social phobia are allowed to participate)\n* Have current primary diagnosis of any DSM-IV-TR Axis I disorder except GAD, or a current secondary DSM-IV-TR Axis 1 disorder that requires any pharmacologic treatment (other than those disorders listed below). Primary is defined as the disorder that is the primary focus of treatment\n* Have a history of DSM-IV-TR-defined substance abuse or dependence within the past year, excluding caffeine and nicotine\n* Have a current or previous diagnosis of bipolar disorder, psychotic depression, schizophrenia or other psychotic disorder, anorexia, bulimia, obsessive compulsive disorder, post-traumatic stress disorder, panic disorder, or pervasive development disorder, as judged by the investigator\n* Have 1 or more first-degree relatives (parents or siblings) with diagnosed bipolar I disorder\n* Have a serious or unstable medical illness, psychological condition, clinically significant laboratory or electrocardiogram (ECG) result, hypersensitivity to duloxetine, or its active ingredients, frequent or severe allergic reactions to multiple medications, uncontrolled narrow-angle glaucoma, acute liver injury (for example, hepatitis) or severe cirrhosis (Child-Pugh Class C), or a history of any seizure disorder (other than febrile seizures)\n* Have a significant suicide attempt within 1 year of screening or are currently at risk of suicide in the opinion of the investigator\n* Have initiated, stopped, or changed the type or intensity of psychotherapy within 6 weeks prior to screening. Participants who require a change to psychotherapy between weeks 1 through 10 will be excluded\n* Have a weight less than 20 kilograms at any time during the screening period\n* Female participants who are pregnant, nursing or have recently given birth","healthyVolunteers":false,"sex":"ALL","minimumAge":"7 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hialeah","state":"Florida","zip":"33013","country":"United States","geoPoint":{"lat":25.8576,"lon":-80.27811}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Smyrna","state":"Georgia","zip":"30080","country":"United States","geoPoint":{"lat":33.88399,"lon":-84.51438}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Libertyville","state":"Illinois","zip":"60048","country":"United States","geoPoint":{"lat":42.28308,"lon":-87.95313}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lexington","state":"Kentucky","zip":"40509","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Troy","state":"Michigan","zip":"48083","country":"United States","geoPoint":{"lat":42.60559,"lon":-83.14993}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Gladstone","state":"Missouri","zip":"64118","country":"United States","geoPoint":{"lat":39.20389,"lon":-94.55468}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Omaha","state":"Nebraska","zip":"68198","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cherry Hill","state":"New Jersey","zip":"08002","country":"United States","geoPoint":{"lat":39.93484,"lon":-75.03073}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Rochester","state":"New York","zip":"14618","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cincinnati","state":"Ohio","zip":"45219","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cleveland","state":"Ohio","zip":"44106","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Oklahoma City","state":"Oklahoma","zip":"73103","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Richmond","state":"Virginia","zip":"23230","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bellevue","state":"Washington","zip":"98007","country":"United States","geoPoint":{"lat":47.61038,"lon":-122.20068}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Spokane","state":"Washington","zip":"99202","country":"United States","geoPoint":{"lat":47.65966,"lon":-117.42908}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Insurgentes Cuicuilco","zip":"04530","country":"Mexico","geoPoint":{"lat":19.30701,"lon":-99.18332}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mexico City","zip":"14080","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Monterrey","zip":"64060","country":"Mexico","geoPoint":{"lat":25.68435,"lon":-100.31721}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"San Luis Potosí City","zip":"78200","country":"Mexico","geoPoint":{"lat":22.15234,"lon":-100.97135}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Zona Centro","zip":"37000","country":"Mexico","geoPoint":{"lat":23.73126,"lon":-99.14803}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bloemfontein","zip":"9301","country":"South Africa","geoPoint":{"lat":-29.12107,"lon":26.214}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cape Town","zip":"7530","country":"South Africa","geoPoint":{"lat":-33.92584,"lon":18.42322}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Pretoria","zip":"0042","country":"South Africa","geoPoint":{"lat":-25.74486,"lon":28.18783}}]},"referencesModule":{"references":[{"pmid":"25791145","type":"DERIVED","citation":"Strawn JR, Prakash A, Zhang Q, Pangallo BA, Stroud CE, Cai N, Findling RL. A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2015 Apr;54(4):283-93. doi: 10.1016/j.jaac.2015.01.008. Epub 2015 Jan 29."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"This study had 4 periods: Screening period (1-week), acute treatment period (10-week, double-blind period with flexible duloxetine dosing), extension treatment (18-week period, of which 16 weeks were open-label treatment with flexible duloxetine dosing), and a taper period (2 weeks recommended at discontinuation from study any point after Week 2).","groups":[{"id":"FG000","title":"Duloxetine/Duloxetine","description":"Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period. Duloxetine was provided in 30-mg capsules.\n\nParticipants who received higher doses of duloxetine at the end of treatment period participation received gradually lower doses of duloxetine over the 2-week recommended tapering period, and participants who received the lowest dose of duloxetine or placebo at the end of treatment period participation received placebo over the 2-week recommended tapering period."},{"id":"FG001","title":"Placebo/Duloxetine","description":"Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period. Duloxetine was provided in 30-mg capsules.\n\nParticipants who received higher doses of duloxetine at the end of treatment period participation received gradually lower doses of duloxetine over the 2-week recommended tapering period, and participants who received the lowest dose of duloxetine or placebo at the end of treatment period participation received placebo over the 2-week recommended tapering period."}],"periods":[{"title":"Acute Treatment Period","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Thirty-one (31) participants who discontinued acute treatment did not enter the taper period.","numSubjects":"140"},{"groupId":"FG001","comment":"Twenty-six (26) participants who discontinued acute treatment did not enter the taper period.","numSubjects":"141"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"108"},{"groupId":"FG001","numSubjects":"110"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"31"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Parent/caregiver decision","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"6"}]}]},{"title":"Extension Treatment Period","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Nineteen (19) participants who discontinued extension treatment did not enter the taper period.","numSubjects":"108"},{"groupId":"FG001","comment":"Twenty-three (23) participants who discontinued extension treatment did not enter the taper period.","numSubjects":"110"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"Thirty-nine (39) participants who completed extension treatment did not enter the taper period.","numSubjects":"81"},{"groupId":"FG001","comment":"Thirty-five (35) participants who completed extension treatment did not enter the taper period.","numSubjects":"83"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"27"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Parent/Caregiver Decision","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]}]},{"title":"Taper Period","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"51"},{"groupId":"FG001","numSubjects":"57"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"46"},{"groupId":"FG001","numSubjects":"54"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Parent/Caregiver Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants, excluding 9 participants from 1 site with major quality issues.","groups":[{"id":"BG000","title":"Duloxetine/Duloxetine","description":"Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period. Duloxetine was provided in 30-mg capsules.\n\nParticipants who received higher doses of duloxetine at the end of treatment period participation received gradually lower doses of duloxetine over the 2-week recommended tapering period, and participants who received the lowest dose of duloxetine or placebo at the end of treatment period participation received placebo over the 2-week recommended tapering period."},{"id":"BG001","title":"Placebo/Duloxetine","description":"Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period. Duloxetine was provided in 30-mg capsules.\n\nParticipants who received higher doses of duloxetine at the end of treatment period participation received gradually lower doses of duloxetine over the 2-week recommended tapering period, and participants who received the lowest dose of duloxetine or placebo at the end of treatment period participation received placebo over the 2-week recommended tapering period."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"135"},{"groupId":"BG001","value":"137"},{"groupId":"BG002","value":"272"}]}],"measures":[{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"7 to 11 years","categories":[{"measurements":[{"groupId":"BG000","value":"62"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"128"}]}]},{"title":"12 to 17 years","categories":[{"measurements":[{"groupId":"BG000","value":"73"},{"groupId":"BG001","value":"71"},{"groupId":"BG002","value":"144"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"70"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"145"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"127"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"77"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"88"},{"groupId":"BG001","value":"88"},{"groupId":"BG002","value":"176"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"19"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"13"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"19"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"112"},{"groupId":"BG001","value":"111"},{"groupId":"BG002","value":"223"}]}]},{"title":"More than 1 race","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"15"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"98"},{"groupId":"BG001","value":"99"},{"groupId":"BG002","value":"197"}]}]},{"title":"Mexico","categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"52"}]}]},{"title":"South Africa","categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"23"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to 10-Week Endpoint in the Pediatric Anxiety Rating Scale (PARS) Severity Score Evaluated for Symptoms Identified on the Generalized Anxiety Subsection of the PARS Symptom Checklist","description":"PARS severity score for GAD was assessed for all symptoms identified in the generalized anxiety section of the PARS symptom checklist. PARS severity score for GAD was derived by summing 5 of 7 severity/impairment/interference items (2, 3, 5, 6, 7); each item ranged from 0 (none) to 5 (extreme severity/impairment/interference). PARS severity scores for GAD ranged from 0 (none) to 25 (extreme severity), with a score of 15 indicating moderate illness severity. Least squares (LS) mean was calculated using a mixed-effects model repeated measures (MMRM) approach adjusted for baseline, pooled investigator, age category, visit, treatment, treatment\\*visit, age category\\*visit, and baseline\\*visit.","populationDescription":"Randomized participants with a baseline and at least 1 post-baseline PARS severity score for GAD during the acute treatment period, excluding 9 participants from 1 site with major quality issues.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 10 weeks","groups":[{"id":"OG000","title":"Duloxetine (Acute Treatment)","description":"Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period."},{"id":"OG001","title":"Placebo (Acute Treatment)","description":"Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"133"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.70","spread":"0.502"},{"groupId":"OG001","value":"-7.05","spread":"0.500"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"Least squares (LS) mean difference","paramValue":"-2.65","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.03","ciUpperLimit":"-1.27","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.700"}]},{"type":"SECONDARY","title":"Response Rate at Endpoint for Generalized Anxiety Disorder (GAD) Using Pediatric Anxiety Rating Scale (PARS) Severity Score for GAD","description":"Response rate was defined as the percentage of participants having a 50% improvement from baseline to endpoint on the PARS severity score for GAD. PARS severity score for GAD was assessed for all symptoms identified in the generalized anxiety section of the PARS symptom checklist. PARS severity score for GAD was derived by summing 5 of 7 severity/impairment/interference items (2, 3, 5, 6, 7); each item ranged from 0 (none) to 5 (extreme severity/impairment/interference). PARS severity scores for GAD ranged from 0 (none) to 25 (extreme severity), with a score of 15 indicating moderate illness severity.","populationDescription":"Randomized participants with a baseline and at least 1 post-baseline PARS severity score for GAD \\[last observation carried forward (LOCF)\\] during the acute treatment period, excluding 9 participants from 1 site with major quality issues.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, 10 weeks","groups":[{"id":"OG000","title":"Duloxetine (Acute Treatment)","description":"Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period."},{"id":"OG001","title":"Placebo (Acute Treatment)","description":"Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"133"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":"4.8"},{"groupId":"OG001","value":"37","spread":"4.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 10-Week Endpoint on the Pediatric Anxiety Rating Scale (PARS) Severity Total Score Evaluated for All Symptoms Identified on the PARS Symptom Checklist Symptoms","description":"PARS severity total score was assessed for all symptoms identified on the PARS symptom checklist. PARS severity total score was derived by summing 5 of 7 severity/impairment/interference items (2, 3, 5, 6, 7); each item ranged from 0 (none) to 5 (extreme severity/impairment/interference). PARS severity total scores ranged from 0 (none) to 25 (extreme severity), with a score of 15 indicating moderate illness severity. Least squares (LS) mean was calculated using a mixed-effects model repeated measures (MMRM) approach adjusted for treatment, pooled investigator, visit, baseline, age category, treatment\\*visit, baseline\\*visit, and age category\\*visit.","populationDescription":"Randomized participants with a baseline and at least 1 post-baseline PARS severity total score during the acute treatment period, excluding 9 participants from 1 site with major quality issues.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 10 weeks","groups":[{"id":"OG000","title":"Duloxetine (Acute Treatment)","description":"Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period."},{"id":"OG001","title":"Placebo (Acute Treatment)","description":"Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"133"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.15","spread":"0.479"},{"groupId":"OG001","value":"-6.36","spread":"0.477"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 10-Week Endpoint on the Clinical Global Impression of Severity (CGI-S) Scale","description":"The CGI-S scale evaluated the severity of illness at the time of assessment. Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill). Higher scores indicated a greater severity of illness. Least squares (LS) mean was calculated using a mixed-effects model repeated measures (MMRM) approach adjusted for treatment, pooled investigator, visit, baseline, age category, treatment\\*visit, baseline\\*visit, and age category\\*visit.","populationDescription":"Randomized participants with a baseline and at least 1 post-baseline CGI-S score during the acute treatment period, excluding 9 participants from 1 site with major quality issues.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 10 weeks","groups":[{"id":"OG000","title":"Duloxetine (Acute Treatment)","description":"Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period."},{"id":"OG001","title":"Placebo (Acute Treatment)","description":"Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"133"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.93","spread":"0.114"},{"groupId":"OG001","value":"-1.38","spread":"0.113"}]}]}]},{"type":"SECONDARY","title":"Remission Rate at Endpoint for Generalized Anxiety Disorder (GAD) Using Clinical Global Impressions of Severity (CGI-S) Scale","description":"Remission rate was defined as the percentage of participants having a CGI-S score ≤2 at endpoint. The CGI-S scale evaluated the severity of illness at the time of assessment. Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill). Higher scores indicated a greater severity of illness.","populationDescription":"Randomized participants with at least 1 post-baseline CGI-S score \\[last observation carried forward (LOCF)\\] during the acute treatment period, excluding 9 participants from 1 site with major quality issues.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"10 weeks","groups":[{"id":"OG000","title":"Duloxetine (Acute Treatment)","description":"Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period."},{"id":"OG001","title":"Placebo (Acute Treatment)","description":"Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"133"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"30"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 10-Week Endpoint in the Children's Global Assessment Scale (CGAS)","description":"The CGAS was a clinician-rated assessment of general functioning. CGAS raw scores ranged from 1 (greatest impairment) to 100 (superior functioning). Lower scores indicated a lower level of functioning and greater impairment. Least squares (LS) mean from an analysis of covariance (ANCOVA) was adjusted for treatment, pooled investigator, baseline, and age category.","populationDescription":"Randomized participants with a baseline and at least 1 post-baseline \\[last observation carried forward (LOCF)\\] CGAS score during the acute treatment period, excluding 9 participants from 1 site with major quality issues.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 10 weeks","groups":[{"id":"OG000","title":"Duloxetine (Acute Treatment)","description":"Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period."},{"id":"OG001","title":"Placebo (Acute Treatment)","description":"Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"124"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.14","spread":"1.232"},{"groupId":"OG001","value":"12.16","spread":"1.219"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants During the 10-Week Period With Treatment-Emergent (New or Worsening) Suicidal Ideation as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)","description":"The C-SSRS captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal ideation: a \"yes\" answer to any 1 of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Results reported as percentage of participants with treatment-emergent (new or worsening) suicidal ideation from baseline=(number of participants with changes compared to baseline/total number of participants at risk)\\*100.","populationDescription":"Randomized participants with a baseline and at least 1 post-baseline C-SSRS suicidal ideation score during the acute treatment period, whose baseline maximum C-SSRS suicidal ideation score was \\<5. Nine (9) participants from 1 site with major quality issues were excluded.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline up to 10 weeks","groups":[{"id":"OG000","title":"Duloxetine (Acute Treatment)","description":"Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period."},{"id":"OG001","title":"Placebo (Acute Treatment)","description":"Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"134"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9"},{"groupId":"OG001","value":"5.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants During the 10-Week Period With Treatment-Emergent (New or Worsening) Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)","description":"The C-SSRS captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior: a \"yes\" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Reported as percentage of participants with treatment-emergent (new or worsening) suicidal behavior from baseline=(number of participants with changes compared to baseline/total number of participants at risk)\\*100.","populationDescription":"Randomized participants with a baseline and at least 1 post-baseline C-SSRS suicidal behavior score during the acute treatment period, excluding 9 participants from 1 site with major quality issues.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline up to 10 weeks","groups":[{"id":"OG000","title":"Duloxetine (Acute Treatment)","description":"Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period."},{"id":"OG001","title":"Placebo (Acute Treatment)","description":"Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"134"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]}]},{"type":"SECONDARY","title":"Change From 10-Week to 28-Week Endpoint in the Pediatric Anxiety Rating Scale (PARS) Severity Score Evaluated for Symptoms Identified on the Generalized Anxiety Subsection of the PARS Symptom Checklist","description":"PARS severity score for GAD was assessed for all symptoms identified in the generalized anxiety section of the PARS symptom checklist. PARS severity score for GAD was derived by summing 5 of 7 severity/impairment/interference items (2, 3, 5, 6, 7); each item ranged from 0 (none) to 5 (extreme severity/impairment/interference). PARS severity scores for GAD ranged from 0 (none) to 25 (extreme severity), with a score of 15 indicating moderate illness severity. Least squares (LS) mean was calculated using a mixed-effects model repeated measures (MMRM) approach adjusted for pooled investigator, visit, baseline, age category, baseline\\*visit, and age category\\*visit within reporting groups.","populationDescription":"Randomized participants with a PARS severity score for GAD during the acute treatment period and at least 1 PARS severity score for GAD during the extension treatment period, excluding 9 participants from 1 site with major quality issues.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"10 weeks, 28 weeks","groups":[{"id":"OG000","title":"Duloxetine/Duloxetine (Extension Treatment)","description":"Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period."},{"id":"OG001","title":"Placebo/Duloxetine (Extension Treatment)","description":"Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"105"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.33","spread":"0.352"},{"groupId":"OG001","value":"-5.15","spread":"0.452"}]}]}]},{"type":"SECONDARY","title":"Change From 10-Week to 28-Week Endpoint on the Pediatric Anxiety Rating Scale (PARS) Severity Total Score Evaluated for All Symptoms Identified on the PARS Symptom Checklist Symptoms","description":"PARS severity total score was assessed for all symptoms identified on the PARS symptom checklist. PARS severity total score was derived by summing 5 of 7 severity/impairment/interference items (2, 3, 5, 6, 7); each item ranged from 0 (none) to 5 (extreme severity/impairment/interference). PARS severity total scores ranged from 0 (none) to 25 (extreme severity), with a score of 15 indicating moderate illness severity. Least squares (LS) mean was calculated using a mixed-effects model repeated measures (MMRM) approach adjusted for pooled investigator, visit, baseline, age category, baseline\\*visit, and age category\\*visit within reporting groups.","populationDescription":"Randomized participants with a PARS severity total score during the acute treatment period and at least 1 PARS severity total score during the extension treatment period, excluding 9 participants from 1 site with major quality issues.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"10 weeks, 28 weeks","groups":[{"id":"OG000","title":"Duloxetine/Duloxetine (Extension Treatment)","description":"Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period."},{"id":"OG001","title":"Placebo/Duloxetine (Extension Treatment)","description":"Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"105"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.32","spread":"0.357"},{"groupId":"OG001","value":"-5.26","spread":"0.432"}]}]}]},{"type":"SECONDARY","title":"Change From 10-Week to 28-Week Endpoint on the Clinical Global Impression of Severity (CGI-S) Scale","description":"The CGI-S scale evaluated the severity of mental illness at the time of assessment. Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill). Higher scores indicated a greater severity of illness. Least squares (LS) mean was calculated using a mixed-effects model repeated measures (MMRM) approach adjusted for pooled investigator, visit, baseline, age category, baseline\\*visit, and age category\\*visit within reporting groups.","populationDescription":"Randomized participants with a CGI-S score during the acute treatment period and at least 1 CGI-S score during the extension treatment period, excluding 9 participants from 1 site with major quality issues.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"10 weeks, 28 weeks","groups":[{"id":"OG000","title":"Duloxetine/Duloxetine (Extension Treatment)","description":"Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period."},{"id":"OG001","title":"Placebo/Duloxetine (Extension Treatment)","description":"Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"105"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.76","spread":"0.093"},{"groupId":"OG001","value":"-1.17","spread":"0.088"}]}]}]},{"type":"SECONDARY","title":"Change From 10-Week to 28-Week Endpoint in the Children's Global Assessment Scale (CGAS)","description":"The CGAS was a clinician-rated assessment of general functioning. CGAS raw scores ranged from 1 (greatest impairment) to 100 (superior functioning). Lower scores indicated a lower level of functioning and greater impairment. Least squares (LS) mean from an analysis of covariance (ANCOVA) was adjusted for pooled investigator, baseline, and age category within reporting groups.","populationDescription":"Randomized participants with a CGAS score during the acute treatment period and at least 1 CGAS score during the extension treatment period \\[last observation carried forward (LOCF)\\], excluding 9 participants from 1 site with major quality issues.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"10 weeks, 28 weeks","groups":[{"id":"OG000","title":"Duloxetine/Duloxetine (Extension Treatment)","description":"Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period."},{"id":"OG001","title":"Placebo/Duloxetine (Extension Treatment)","description":"Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"105"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.32","spread":"1.19"},{"groupId":"OG001","value":"10.48","spread":"1.03"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants During the 18-Week Extension Period With Treatment-Emergent (New or Worsening) Suicidal Ideation as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)","description":"The C-SSRS captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal ideation: a \"yes\" answer to any 1 of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Results reported as percentage of participants with treatment-emergent (new or worsening) suicidal ideation from baseline=(number of participants with changes compared to baseline/total number of participants at risk)\\*100.","populationDescription":"Randomized participants with a C-SSRS suicidal ideation score \\<5 at the last 2 visits in the acute treatment period and at least 1 C-SSRS suicidal ideation score during the extension treatment period. Nine (9) participants from 1 site with major quality issues were excluded.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"10 weeks up to 28 weeks","groups":[{"id":"OG000","title":"Duloxetine/Duloxetine (Extension Treatment)","description":"Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period."},{"id":"OG001","title":"Placebo/Duloxetine (Extension Treatment)","description":"Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"105"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants During the 18-Week Extension Period With Treatment-Emergent (New or Worsening) Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)","description":"The C-SSRS captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior: a \"yes\" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Reported as percentage of participants with treatment-emergent (new or worsening) suicidal behavior from baseline=(number of participants with changes compared to baseline/total number of participants at risk)\\*100.","populationDescription":"Randomized participants with a C-SSRS suicidal behavior score at the last 2 visits in the acute treatment period and at least 1 C-SSRS suicidal behavior score during the extension treatment period, excluding 9 participants from 1 site with major quality issues.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"10 weeks up to 28 weeks","groups":[{"id":"OG000","title":"Duloxetine/Duloxetine (Extension Treatment)","description":"Participants received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period."},{"id":"OG001","title":"Placebo/Duloxetine (Extension Treatment)","description":"Participants received placebo capsules orally, QD for 10 weeks during the acute treatment period and flexible doses of duloxetine 30 to 120 mg orally, QD for 18 weeks during the optional extension treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"105"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"2","description":"Serious adverse events (SAEs) and non-serious AEs were reported for all randomized participants, excluding 9 participants from 1 site with major quality issues.","eventGroups":[{"id":"EG000","title":"Duloxetine","description":"Adverse events (AEs) during the acute treatment period for participants who received flexible doses of duloxetine 30 to 120 milligrams (mg) orally, once daily (QD) for 10 weeks.","seriousNumAffected":1,"seriousNumAtRisk":135,"otherNumAffected":106,"otherNumAtRisk":135},{"id":"EG001","title":"Placebo","description":"AEs during the acute treatment period for participants who received placebo capsules orally, QD for 10 weeks.","seriousNumAffected":0,"seriousNumAtRisk":137,"otherNumAffected":90,"otherNumAtRisk":137},{"id":"EG002","title":"Duloxetine/Duloxetine-Extension Treatment","description":"AEs during the extension treatment period for participants who received flexible doses of duloxetine 30 to 120 mg orally, QD during both the acute and extension treatment periods (up to 28 weeks).","seriousNumAffected":2,"seriousNumAtRisk":104,"otherNumAffected":73,"otherNumAtRisk":104},{"id":"EG003","title":"Placebo/Duloxetine-Extension Treatment","description":"AEs during the extension treatment period for participants who received placebo capsules orally, QD during the acute treatment period (10 weeks) and flexible doses of duloxetine 30 to 120 mg orally, QD during the extension treatment period (up to 18 weeks).","seriousNumAffected":2,"seriousNumAtRisk":106,"otherNumAffected":73,"otherNumAtRisk":106},{"id":"EG004","title":"Duloxetine-Taper","description":"AEs during the taper period for participants who were dispensed duloxetine prior to entering the taper phase. Participants who received higher doses of duloxetine at the end of treatment period participation received gradually lower doses of duloxetine over the 2-week recommended tapering period.","seriousNumAffected":1,"seriousNumAtRisk":97,"otherNumAffected":12,"otherNumAtRisk":97},{"id":"EG005","title":"Placebo-Taper","description":"AEs during the taper period for participants who were dispensed placebo prior to entering the taper phase. Participants who received the lowest dose of duloxetine or placebo at the end of treatment period participation received placebo over the 2-week recommended tapering period.","seriousNumAffected":1,"seriousNumAtRisk":7,"otherNumAffected":1,"otherNumAtRisk":7}],"seriousEvents":[{"term":"Adenoiditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":135},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":104},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":135},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":104},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Acute psychosis","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":135},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Bipolar disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":135},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Self-injurious ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":135},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"SAE reported for 1 participant (Duloxetine/Duloxetine group) during the extension treatment period and resolved during the duloxetine-taper period. The SAE was counted in both periods, although it was not new or worsening during the taper period.","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":135},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":104},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":97},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]}],"otherEvents":[{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":135},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":135},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":137},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":135},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":137},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":104},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":106},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":135},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":137},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":135},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":137},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":104},{"groupId":"EG003","numEvents":6,"numAffected":5,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":135},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":28,"numAtRisk":135},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":137},{"groupId":"EG002","numEvents":10,"numAffected":10,"numAtRisk":104},{"groupId":"EG003","numEvents":16,"numAffected":13,"numAtRisk":106},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":22,"numAtRisk":135},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":137},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":104},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":135},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":104},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":135},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":137},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":104},{"groupId":"EG003","numEvents":9,"numAffected":9,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Irritability","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":135},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":137},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":104},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":106},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":135},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":137},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":104},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":135},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":137},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":104},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Ear infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":135},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":137},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":104},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":135},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":104},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":106},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":135},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":137},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":104},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":135},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":137},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":104},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":135},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":137},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":104},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":135},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":104},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pharyngitis streptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":135},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":137},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":104},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":135},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":137},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":104},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":135},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":137},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":104},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":135},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":137},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":104},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":135},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":135},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":137},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":104},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":20,"numAtRisk":135},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":137},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":104},{"groupId":"EG003","numEvents":10,"numAffected":9,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Increased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":135},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":137},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":135},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":137},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":104},{"groupId":"EG003","numEvents":9,"numAffected":7,"numAtRisk":106},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":27,"numAtRisk":135},{"groupId":"EG001","numEvents":29,"numAffected":23,"numAtRisk":137},{"groupId":"EG002","numEvents":17,"numAffected":13,"numAtRisk":104},{"groupId":"EG003","numEvents":13,"numAffected":11,"numAtRisk":106},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":135},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":137},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Psychomotor hyperactivity","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":135},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":137},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":104},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Sedation","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":135},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":16,"numAtRisk":135},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":137},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":104},{"groupId":"EG003","numEvents":11,"numAffected":8,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":135},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":104},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":135},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":137},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":104},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Intentional self-injury","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":135},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":104},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":70},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":75},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":53},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":59},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":47},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":3}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":135},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":104},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":135},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":135},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":137},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":104},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":135},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":137},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":104},{"groupId":"EG003","numEvents":4,"numAffected":2,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":135},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":137},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":104},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hot flush","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":135},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":106},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":97},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Nine (9) randomized participants (5 duloxetine, 4 placebo) from 1 site were excluded from efficacy and safety analyses due to major quality issues at that site."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D001008","term":"Anxiety Disorders"}],"ancestors":[{"id":"D001523","term":"Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068736","term":"Duloxetine Hydrochloride"}],"ancestors":[{"id":"D013876","term":"Thiophenes"},{"id":"D013457","term":"Sulfur Compounds"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}